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Background: The CWxP motif of transmembrane helix 6 (x: any residue) is highly conserved in class A GPCRs.
Within this motif, W6.48 is a big star in the theory of the global “toggle switch” because of its key role in the
activation mechanism of GPCRs upon ligand binding. With all footlights focused on W6.48, the reason why the
preceding residue, C6.47, is largely conserved is still unknown. The present study is aimed to fill up this lack of
knowledge by characterizing the role of C6.47 of the CWxP motif.
Results: A complete analysis of available crystal structures has been made alongside with molecular dynamics
simulations of model peptides to explore a possible structural role for C6.47.
Conclusions: We conclude that C6.47 does not modulate the conformation of the TM6 proline kink and propose
that C6.47 participates in the rearrangement of the TM6 and TM7 interface accompanying activation.Background
G protein-coupled receptors (GPCRs) are versatile signal-
ing molecules that regulate a vast amount of cellular pro-
cesses responding to hormones and neurotransmitters [1].
They are present in almost every eukaryotic organism, in-
cluding fungi and plants, and they are highly diversified in
mammalian genomes, representing 2-3% of the human
proteome [2]. GPCRs transduce external signals as diverse
as photons, odors, pheromones, biogenic amines, neuro-
peptides, proteases, glycoprotein hormones and ions
(among others) into the cell interior. The response is oper-
ated through second messenger cascades controlled by
both heterotrimeric guanine nucleotide-binding proteins
(G-proteins) [3] or G protein-independent pathways [4].
GPCRs constitute one of the most important pharmaceut-
ical targets, with 30% of marketed drugs acting through
them [5]. Mammalian GPCRs are classified in three major
families or classes (A, B and C) from which class A is the
largest and most studied [6]. Although each GPCR plays a
single role in mediating physiological response, many con-
served sequential and structural features are encountered
among them, mainly near the cytoplasmic part where re-
ceptors bind to the G protein [7,8]. Towards the extracel-
lular side, divergence increases [9,10] because of the wide
diversity of ligands that need to be bound.* Correspondence: arnau.cordomi@uab.cat
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reproduction in any medium, provided the orThe relatively large repertoire of class A GPCR crystal
structures currently available [11-29] (including complexes
with agonists, antagonists and inverse agonists) shed light
into the understanding of GPCRs’ molecular architecture,
as well as on the events responsible for signal transmission
(see Table 1). Receptors are thought to be in equilibrium
among different states, being inactive ones the most popu-
lated in absence of ligand. Agonist binding alters the ener-
getic balance towards actives states triggering activation
responses. This implies changes in the conformation of a
few residues that are responsible for the formation and
disruption of hydrophobic and hydrogen-bond interac-
tions between specific groups of residues. Most of the
highly conserved residues often belong to “micro-switches”
that swap between different conformations, and constitute
an extended allosteric interface between transmembrane
(TM) domains [30]. These micro-switches span from the
extracellular part to the intracellular G-protein binding
site and regulate the equilibrium between inactive and ac-
tive conformations. This may trigger, eventually, global
movements connecting ligand binding with intracellular
signaling. R3.50 and D3.49 (of the DRY motif; Ballesteros
and Weinstein numbering scheme will be used through this
text [31]), Y5.58, Y7.53 (of the NPxxY motif), and W6.48
(of the CWxP motif), are some of the most studied micro-
switches [32-36].
The CWxP motif in TM6 (6.47-6.50) is highly conserved
in non-olfactory class A GPCRs, with C6.47, W6.48 and
P6.50 present in 71%, 78% and 98% of sequences,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 The 6.47-7.45 interaction in the analyzed crystal structures
Crystal structure TM6-TM7 hydrogen bond
Receptor name Structure name PDB ID Res.(Å) Pair N7.45 D⋯ A (Å) Cβ-D⋯A (°)
β2-adrenergic β2AR
INV 2RH1 [11] 2.4 C6.47-N7.45 CO 3.8 84.5
β2ARAGO 3SN6 [12] 3.2 CO 4.4 81.2
β1-adrenergic (turkey) β1ARINV 2VT4 [13] 2.7 C6.47-N7.45 CO 3.7 79.3
β1ARAGO 2Y02 [14] 2.6 CO 3.9 85.3
Dopamine D3 D3RINV 3PBL [15] 2.9 C6.47-N7.45 CO 3.8 81.6
Histamine H1 H1RINV 3RZE [16] 3.1 C6.47-N7.45 CO 4.2 80.9
Adenosine A2A A2AR
INV 4EIY [17] 1.8 C6.47-N7.45 NH2 3.9 84.5
A2AR
AGO 2YDV [18] 2.6 CO 4.3 74.4
κ opioid κORINV 4DJH [19] 2.9 C6.47-N7.45 CO 4.1 81.2
μ opioid (mouse) μORINV 4DKL [20] 2.8 C6.47-N7.45 CO 3.6 87.5
δ opioid (mouse) δORINV 4EJ4 [21] 3.4 C6.47-N7.45 NH2 3.8 89.8
N/OFQ Opioid N/OFQINV 4EA3 [22] 3.0 C6.47-N7.45 NH2 4.2 85.6
Sphingosine 1-phosph. 1 S1PR1
INV 3V2Y [23] 2.8 C6.47-N7.45 NH2 3.4 81.1
CXCR4 chemokine CXCR4INV 3ODU [24] 2.5 C6.47-H7.45 - - -
M2 musc. ach. M2RINV 3UON [25] 3.0 T6.47-N7.45 NH2 3.2 120.2
M3 musc. ach. (rat) M3RINV 4DAJ [26] 3.4 T6.47-N7.45 NH2 4 140.7
Rhodopsin (bovine) bRhoINV 1GZM [27] 2.7 C6.47-T7.44 - 3.7 101.8
bRhoAGO 3PQR [28] 2.9 - 8.8 -
Rhodopsin (squid) sRhoINV 2Z73 [29] 2.5 Q6.43-S7.54 - 2.4 111.2
(Left) Crystal structures used within the manuscript (INV: inverse agonist or antagonist; AGO: agonist); Protein Data Bank Identification Code and Resolution;
receptor structures are human unless stated. (Right) Characterization of the TM6-TM7 hydrogen bond: pair involved, N7.45 rotamer (CO/NH2 indicates the closer
group to C6.47 as in their crystal structure), donor(D)-acceptor(A) distance and Cβ-donor(D)···acceptor(A) angle.
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TM6 helix (causing a helix bend of around 35°), far bigger
than a usual Proline in a transmembrane helix (around 20°)
[37]. Because an outward movement of the cytoplasmic
side of TM6 is known to accompany receptor activation, it
was initially proposed that the Pro-kinked helix could act as
a mechanical hinge [38,39]. In fact, these pioneering experi-
ments and computer simulations on rhodopsin originated
one of the central paradigms in GPCR activation: the so-
called “rotamer toggle switch”. This consisted in a
concerted change of C6.47, W6.48 and F6.52 side-chain
rotamers between inactive and active states, which were
thought to originate the opening of TM6 [40]. In specific,
transition of W6.48 from gauche+ to trans and of C6.47
from trans to gauche+ was proposed by Shi and collabora-
tors [38,39]. The low resolution structure of metarhodopsin
I, determined by electron crystallography [41], supported
the rotamer change of W6.48 as did more recent infrared
spectroscopy experiments of rhodopsin photocycle [42].
However, and quite-unexpectedly, none of the available
pairs of inactive-active structure are consistent with these
rotameric changes (see Table 1 and references therein),
questioning the rotamer toggle switch model. Still, it is
known from mutagenesis experiments that W6.48 is essen-
tial for signaling of some (but not all) receptors [40,43]. Onthe other hand, there is no current explanation for the large
conservation of C6.47 and for the effects on activity
reported by various C6.47 mutants. In particular, C6.47T in
β2-adrenergic receptor [39] and C6.47R in thyrotropin
hormone receptor [44], both led to constitutive Gαs acti-
vation. Similarly, C6.47 mutants in cannabinoid receptors
CB1 and CB2 modified both ligand recognition and re-
ceptor activation [45,46].
The present study reports an extensive analysis of the
available GPCRs crystal structures combined with results
from molecular dynamics (MD) simulations of model pep-
tides in a membrane mimic aimed at characterizing the role
of C6.47. Our results support that C6.47 is a key element of
a conserved micro-switch within the TM6/TM7 interface.
We show that Cys side-chain possesses unique physico-
chemical properties and rotameric preferences (compared
to Ser and Thr) that allows formation of specific interac-
tions not possible for other small hydrogen-bonding cap-
able residues.
Results and discussion
Residue prevalence and side chain conformation of
position 6.47
70% of class-A GPCRs have Cys at position 6.47, whereas
the homologous Ser and Thr account, respectively, for only
Olivella et al. BMC Structural Biology 2013, 13:3 Page 3 of 10
http://www.biomedcentral.com/1472-6807/13/310% and 4% of the sequences (see Methods). Accordingly,
most presently available crystal structures of GPCRs contain
cysteine at this position except for muscarinic receptors
M2R and M3R, which feature Thr, and for squid rhodopsin,
which features Ser (see Table 2). This suggests that a small
residue with hydrogen-bonding capabilities is required at
position 6.47, but also a preference for Cys rather than Ser
or Thr. Structural analysis shows that, among receptors
containing C6.47, the residue is in gauche + conformation
(g+) in all cases except rhodopsin (trans, t). M2RINV and
M3RINV feature T6.47 in gauche- (g-) and sRhoINV has
S6.47 in trans conformation. For those receptors in which
both agonist- and inverse agonist-bound structures are
available (β2AR
INV-β2AR
AGO, β1AR
INV-β1AR
AGO, A2AR
INV-
A2AR
AGO, bRhoINV-bRhoAGO) there is no change in 6.47
rotamer conformation. Thus, crystal structures do not
support the rotamer change for residue 6.47 accompanying
receptors activation as hypothesized by Shi et al [38,39].
MD simulations of A/C/T/SxxP model peptides
We have previously shown how specific Ser and Thr
conformers can efficiently modulate the structure of a
neighboring proline-kink by forming hydrogen bonds
with the backbone carbonyl at positions i-3 or i-4 (with
respect to proline, i) [37,47,48]. In the present study, we
performed MD simulations of model peptides containing
Ser, Thr and Cys at position i-4 with respect to proline,
in a hydrophobic solvent (see Method). Analogous pep-
tides containing C/T/SWAP motifs exhibit a similar pro-
file (see Additional file 1: Figure S1). The aim of these
simulations was to establish whether or not Cys couldTable 2 Residues present at positions 6.47 and 7.42-7.48
Receptor
6.47 7.42 7.43
β2-adrenergic Cg+ G Y
β1-adrenergic (turkey) Cg+ G Y
Dopamine D3 Cg+ G Y
Histamine H1 Cg+ G Y
Adenosine A2A Cg+ S H
κ opioid Cg+ G Y
μ opioid (mouse) Cg+ G Y
δ opioid (mouse) Cg+ G Y
N/OFQ Opioid Cg+ G Y
Sphingosine 1-phosph. 1 Cg+ A V
CXCR4 chemokine Cg+ A F
M2 musc. ach. Tg- C Y
M3 musc. ach. (rat) Tg- C Y
Rhodopsin (bovine) Ct A K
Rhodopsin (squid) Sg+ A K
Rotamer of C, S and T (g+/-: gauche+/-, t: trans) is indicated when relevant; residuealter the structure of a regular proline kink and quantify
the extent of the alteration compared to Ser and Thr
[49]. Figure 1 shows the change in Φ and Ψ angles and
in local twists and bends for peptides with respect to the
reference AAAP peptide, for C/T/SAAP motifs with the
C/T/S rotamer fixed to g+, g- or t (see Methods). In
terms of Φ and Ψ, it can be seen that all g- conformers
induce a ~15° decrease in Φ angle profile (relative to the
WT) at position i-3, and an increase (8-9° for Ser and
Thr, 4° for Cys) in Ψ angle profile at position i-4. Trans
conformers of Ser and Thr (but not of Cys) induce a
smaller but parallel effect: ~6° decrease in the Φ angle at
position i-2 (and also at position i-3 for Thr) and ~10°
increase in Ψ angle profile at i-3 position. Regarding
bend profiles, all of them exhibit a bimodal shape, where
Cys g+, Cys t and Ser g+ exhibit the smallest deviations
(<2°) relative to the WT. Finally, twist angle in all g-
conformers exhibits a pronounced decrease in the region
between i-6 and i. Collectively, it can be concluded that
Cg- (blue continuous line) and all rotamers of Ser and
Thr (broken and dotted lines) modify the standard pro-
line kink profile (black line). Opposite, profiles of both
Cg+ and Ct reveal no important alterations of the stand-
ard Pro-kink (continuous lines). Taking in consideration
that Cg- rotamer is forbidden because of steric clash [47]
(see Table 3), cysteine turns out to be the only small
hydrogen-bonding capable residue that does not modify
the profile of a standard Pro-kink in its allowed confor-
mations. On the other hand, Ser and Thr would require
further adaptation of the environment in order to be tol-
erated at position 6.47.Position
7.44 7.45 7.46 7.47 7.48
V N S G F
V N S A F
V N S A L
I N S T L
Tg+/t N S C L
T N S S L
T N S C L
A N S S L
V N S C L
L N S G T
F H C A L
I N S T I
I N S T V
Tg+/t Sg- A V Y
A St A I H
s involved in TM6-TM7 hydrogen bonds are displayed in bold.
Figure 1 Analysis of TM6 irregularities computed from MD
simulations of polyalanine peptides containing the CAAP,
SAAP, TAAP motifs in the gauche-, gauche + and trans
conformers. Difference between average Φ (A) and Ψ (B) dihedral
angles, unit bend (C) and unit twist (D) profiles. CtAAP and Cg+AAP
are the unique peptide conformations that present very similar
helical geometrical parameters to AAAP. Sg+AAP peptide present
certain distortion relative to AAAP peptide and Cg-AAP, Sg-AAP,
StAAP, Tg+AAP, Tg-AAP, TtAAP present the most distorted helical
geometrical parameters relative to AAAP peptide. Bend and twist
angles assigned at position i corresponds to the value computed for
(i-3, i) and (i, i + 3) and for (i-3, i), respectively.
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Having discarded C6.47 as a modulator of TM6 kink, it
is then likely that its high conservation is due to specific
interactions played by the thiol group. Crystal structures
show that the central segments of both TM6 and TM7 are
in intimate contact. The maximum proximity is found be-
tween residues 6.47 and 7.42 (~3.5 Å within the closest
atoms). Position 6.47 is precisely the hinge of the rigid
body movement of the cytoplasmic side of TM6 associated
to GPCR activation [28,50,51]. Figure 2A shows a detailed
view centered at C6.47 for β2AR
INV structure (PDB:2RH1)
taken as representative. It can be seen that the thiol group
is surrounded by three aliphatic residues (T6.43, L6.46,
V7.44), one aromatic residue (F6.48), but also by hydrogen
bond-capable groups (backbone carbonyl groups of resi-
dues 6.43 and 7.41 and the side chain of N7.45). This dual
nature at the environment of 6.47 is common to the
remaining structures and perfectly suits the physiochem-
ical properties of Cys thiol group. Analysis of proteins of
known structures show that cysteine environment are
closer to those of Ile methyl groups than to Ser [52]. On
the other hand, Cys is a moderately good hydrogen-bond
donor as demonstrated by the fact that more than two
thirds of the thiol groups in the Protein Data Bank or the
Cambridge Structural Database co-occur with suitable ac-
ceptors, manly carbonyl groups [53-57]. Cysteine has also
been described to participate in thiol- aromatic π-type
hydrogen bonds [58].
Based on molecular modeling and site-directed mutagen-
esis studies, a C6.47-N7.45 hydrogen bond interaction has
recently been proposed in the gonadotropin-releasing hor-
mone receptor [59]. Since all receptors with availableTable 3 Population of C/S/T rotamers in transmembrane
helices from crystal structures
Residue Conformation (%)
gauche- gauche+ trans
Cysteine 0 71 29
Threonine 15 84 1
Serine 20 52 28
Data arranged from reference [47].
Figure 2 The TM6-TM7 interface in β2AR
INV structure. A) Hydrophobic residues (white surface) and free carbonyl groups (red) surrounding
C6.47 (grey surface). B-D) Hydrogen bond network at the TM6 and TM7 interface (indicated by dotted lines). B) In β2ARINV (left) C6.47 forms a
hydrogen bond with N7.45 and eventually with the backbone of 6.43; in β2ARAGO (right) the hydrogen bond between 6.47 and N7.45 is broken
and C6.47 interacts only with the backbone of 6.43. C) sRHOINV features Q6.43 bridging S6.47 and S7.45. D) In RHOINV (left) C6.47 is interacting
with T7.44 g+; in RHOAGO the hydrogen bond between Cys 6.47 and T7.44 has broken. Color code is as follows: TM6 (blue), TM7 (pale red).
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sRho (contain S:12%) and CXCR4 (contains H:8%) we
assessed, by conducting systematic analysis on the available
crystal structures, if this interaction was likely to exist in
other GPCRs.
Available crystal structures differ in the assignment of
CO and NH2 groups for N7.45 (see Table 1). This it is not
surprising because even at 1.8 Å resolution (the highest
obtained for a GPCR structure; see Table 1) it is not pos-
sible to correctly assign all side chain rotamers. Since it is
unlikely that the orientation of the CO/NH2 groups of
N7.45 is not the same in all receptors (this position is
surrounded by many conserved residues) we evaluated the
two possible orientations using NQ-Flipper (see Methods)
[60]. The results revealed that the conformer present in
β2AR
INV (PDB:2RH1) is the most favorable in all struc-
tures. We, therefore, performed our analysis assuming the
rotamer present in β2AR
INV as the correct one. Table 1
displays S(Cys6.47) · · · O(Asn7.45) distances and Cβ-
S · · · O angles measured on the crystal structures of
Asn7.45-containing receptors (see Methods). In all struc-
tures containing C6.47 except β2AR
AGO structure (3SN6),
geometries are compatible with the existence of a hydro-
gen bond between C6.47 and N7.45 [53-57]. It should be
noted that sulfur hydrogen bond has a strong dispersion
energy component [61] and, therefore, the directionalityof the hydrogen bond is less pronounced than in conven-
tional hydrogen bonds, leading to flat potential energy sur-
faces that are attractive even at large distances [54,62].
Figure 2B shows a comparison between β2AR
INV and
β2AR
AGO, displaying the breakage of the C6.47 · · · N7.45
hydrogen bond upon agonist binding. In parallel, it can be
seen in the figure that carbonyl group of 6.43 in β2AR
INV
is oriented toward the amide group of C6.47, whereas in
β2AR
AGO it points towards thiol C6.47 group.
As a result, there is a decrease in the Cys6.47(S) · · · 6.43
(backbone CO) distance, which suggests the stabilization of
an alternative hydrogen bond in β2AR
AGO. This leads us to
propose that the breakage of the C6.47-N7.45 hydrogen
bond is related to activation in β2AR. For A2AR the trend of
that withdrawnness of N7.45 from C6.47 is clearly
maintained. The fact that β1AR
AGO and A2AR
AGO struc-
tures reflect a smaller change as compared to β2AR
AGO
could be due to the fact that the structures do not account
for fully active-like states, as it has previously been pro-
posed [18,63]. Possible reasons could be the lack of TM6
opening (maybe because of absence of G-protein) or, in the
case of β1AR
AGO, the presence of thermostabilizing muta-
tions (including F7.48M contacting C6.47). On the other
hand, H1RINV, known for its high basal activity, exhibits a
distance in between β2AR
INV and β2AR
AGO even in pres-
ence of antagonist [16].
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a Thr in position 6.47. Despite that M2RINV and M3RINV
exhibit the analogous hydrogen bond interaction between
T6.47 and N7.45. The rotamer for Thr is g-, despite g+ is
the most populated rotamer for Thr (see Table 2). This
anomaly seems to originate from the steric clash that Thr
methyl group would give with TM7 in the latter conformer.
Rhodopsins belong to the small group of receptors that
contain S7.45. Because serine is too short to reach the side-
chain of 6.47, rhodopsins seem to have adopted alternative
mechanisms to control TM6-TM7 interface. This could be
related with the fact that retinal is attached to the neighbor-
ing K7.43. Figure 2C displays the structure of sRHOINV
that, oddly, features S6.47 in the g+ rotamer conformation.
It can be seen that the receptor contains residue Q6.43 that
bridges S6.47 and S7.45. In the case of bRho (Figure 2D),
bRhoINV contains an alternative TM6-TM7 hydrogen bondFigure 3 Hydrogen bond network associated to C6.47 in both inverse
and bRho (B). Panel A: C6.47 hydrogen bonds N7.45 which retains N7.49, av
interaction releases (right) N7.49 permitting its interaction with D2.50. Panel B
permits N7.49 to form a hydrogen bond with D2.50. Helices are colored as fo
remaining helices have been omitted for better clarity. Relevant side-chains ar
lines. A crystallographic water molecule is shown as spheres.between C6.47 and T7.44. Comparison between bRhoINV
and bRhoAGO reveals that in the former, trans C6.47 forms
a hydrogen with g- T7.44, whereas in the latter, T7.44 has
changed conformation to trans, breaking C6.47-T7.44
interaction (see Figure 2D). Thus, as in β2AR
INV/β2AR
AGO
pair, there is a breakage of the C6.47-TM7 hydrogen bond
associated to activation.
CXCR4
INV is the only resolved receptor whose sequence
contains H7.45 (instead of Asn). Although histidine is 87%
conserved in chemokine receptors, CXCR4INV shows no
(direct) interaction between 6.47 and H7.45.
6.47 modulates D2.50-N7.49 interaction
In β2AR
INV N7.45 and N7.49 side chains form a water-
mediated hydrogen bond. In β2AR
AGO, release of N7.45
from C6.47 permits N7.45 to free N7.49 side-chain (of the
NPxxY motif) from N7.44, enabling the interaction-agonist (left) and agonist (right) bound structures of β2AR (A)
oiding interaction of the latter with D2.50 (left). Breaking of C6.47-N7.45
: the release of both C6.47-T7.44 and Y7.48-N7.49 hydrogen bonds (left),
llows: TM1:white, TM2:gold, TM3:red, TM6:blue and TM7:pale-red. The
e shown as sticks (cyan) and hydrogen bonds are indicated by dashed
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reinforced by conformation changes of residue S3.39 from
g+ (pointing towards TM3’s backbone in β2AR
INV) to trans
(interacting with D2.50 in β2AR
AGO). Unsurprisingly,
S3.39 is highly conserved (71%) in class A GPCRs. Thus,
C6.47-N7.45 interaction keeps N7.49 away from D2.50
and disruption of this hydrogen bond favors N7.49-D2.50
interaction.
In bRhoAGO, T7.44(t) allows Y7.48 to interact with the
backbone carbonyl of 7.41. The displacement of Y7.48
away from N7.49 allows the latter to interact with D2.50
through a water molecule resolved in the crystal struc-
ture. On the other hand, interaction C6.47-T7.44 in
bRhoINV disables N7.49-D2.50 interaction and retains
Y7.48 close to N7.49 (Figure 3B). Unsurprisingly, Y7.48
is 80% conserved among opsins, backing the importance
of this residue within this subfamily. Y7.48 could not
populate the conformation found in the crystal if C6.47
would be in the g+ rotamer. This explains that C6.47 is
found in the trans rotamer. On the other hand, sRho
features H7.48 (relatively rare in opsins; 7%). Given the
smaller side chain of His compared to Tyr, residue C6.47
can populate the g+ rotamer in the former. Still, Q6.43
would prevent N7.49 from interacting with D2.50.
Together with Y7.53, N7.49 is described to undergo a
conformational change that helps the release of R3.50
from D/E3.49 (and from D/E6.30 in one third of the re-
ceptors). This permits R3.50 to adopt an extended con-
formation that favors the interaction with the C-terminal
portion of Gα domain of G-proteins [64-66]. These con-
formational changes open a cavity between TMs 3, 5 and
6, allowing G-protein binding [12]. In the context of the
global toggle switch model proposed by Schwartz and col-
laborators [30], where various non-covalent interactions
form an allosteric interface that connects ligand binding
with intracellular signaling, C(S,T)6.47 could be consid-
ered as an intermediate micro-switch modulating inter-
action between N7.45 and N7.49, thus ultimately
modulating TM2-TM7 interaction via N7.49 and D2.50.
In the cascade of events during GPCR activation, C6.47
micro-switch would be preceding N7.49.
The analysis of hydrogen bond networks associated to
position 6.47 reveals that receptors having C(S,T)6.47 in
gauche+/- conformation rarely have hydrogen-bond cap-
able residue at position 7.44 (see Table 2). In this situation,
C(S,T)6.47 forms hydrogen bond with the side chain of
residue at position 7.45. On the other hand, in those struc-
tures where residue 6.47 is in the trans rotamer conform-
ation, position 7.45 contains Ser (too short to permit a
6.47-7.45 hydrogen bond). In such cases C(S,T)6.47 forms a
hydrogen bond with position 7.44 instead. Even with differ-
ences at position 6.47 in rotamer conformation (t/g+/g-)
and, to a lesser extent, in residue occurrence (Cys/Ser/Thr),
all crystal structures are in accordance with a hydrogenbond network that connects residue at 6.47 with N7.49 of
the NPxxY motif and the highly conserved (93%) D2.50, via
N7.45(or S7.44).
Conclusions
The largely conserved Cys6.47 of the CWxP motif of
class-A GPCRs was initially thought to modulate the con-
formation of the TM6 proline-kink through a rotamer
switch during the process of activation. The release of sev-
eral agonist-bound (or active-like) crystal structures
invalidated this possibility, as no conformational change of
this residue has been observed, leaving the role and the
prevalence of Cys6.47 unexplained. The present analysis
of crystal structures suggests that C6.47 has an active role
in rearranging the TM6/7 interface between active and in-
active states. Inactive structures are characterized by an
interaction between the side chains of residues C(S/T)6.47
and 7.44/7.45, and this generates a constraint in the TM6-
TM7 interface that keeps N7.49 (of the NPxxY motif)
away from D2.50. Because active structures do not exhibit
the interaction between 7.44/7.45 and 6.47, the formation
of a hydrogen bond between N7.49 and D2.50 is enabled.
We propose that high conservation of Cys at this position
is attributable to the requirement of a small residue with
ability to form both intra- and extra- main chain hydrogen
bonds without altering TM6 Pro-kink. Cys has specific
rotameric preferences compared to Ser or Thr, and in
addition, the thiol group forms less directional hydrogen
bonds than the hydroxyl group.
Although none of the different approaches presented in
this study corroborates per se our hypothesis, their com-
bination brings to a unique possible role for Cys6.47 in
class A GPCRs: Cys6.47 is the gate keeper of the hydrogen
bond network involving N7.45, N.7.49 and D2.50, one of
the most important micro-switches associated to GPCR
activation.
Methods
Molecular dynamics simulations of model peptides
Four 25-residue long α-helical polyalanine peptides
containing variants of the XAAP (being X = A, C, S and
T) motif at their centers were built using PyMol [67]. Each
peptide was subsequently embedded into an equilibrated
cyclohexane box, to mimic membrane environment. Ten
systems were generated by selecting all possible χ1 con-
formers (gauche+, gauche- and trans) of residue X. All
simulations were performed with the GROMACS 4.0.7
simulation package [68]. The force field for the amino
acids was the ported version of Amber99sb for this simu-
lation package [69]. Cyclohexane parameters were taken
from the methylene groups of Berger’s lipids [70] as
employed elsewhere [71]. Systems were energy minimized
and subsequently subjected to 50 ns MD simulations. Pep-
tides were restrained to its original conformation during
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tion and the analysis was performed on the last 25 ns. The
system was kept at an isotropic pressure of 0.1 MPa using
a Berendsen barostat [72]. Temperature was maintained
constant at 300 K using separate V-rescale thermostats for
the peptide and for cyclohexane [73]. All bonds and
angles were frozen using the LINCS algorithm [74].
Lennard-Jones interactions were computed using a cutoff
of 1.0 nm and the electrostatic interactions were treated
using PME with the same real-space cutoff. Integration of
equations of motion was performed using a time-step
of 2 fs.
For each XAAP peptide, Φ and Ψ backbone dihedrals
and unit bend and unit twist angles within residues i-7 to
i + 4 (with position i containing X = C/S/T/A) were com-
puted. GROMACS tools and HELANAL program [75]
were used for this purpose. Unit twist angle is a useful
measure of local helix distortion interpreted as follows: an
ideal α-helix, with approximately 3.6 residues per turn, has
a twist angle of approximately 100° (360°/3.6). Accord-
ingly, a tighter helical segment contains <3.6 and exhibits
a twist >100°, whereas a wider segment contains >3.6 resi-
dues per turn, resulting in a twist <100°.
Analysis of sequence positions
Frequencies of aminoacids at a specific position were
extracted from GPCRs Motif Searcher (http://lmc.uab.cat/
gmos). All data shown herein corresponds to a sequence
alignment for all human non-olfactory class A GPCRs.
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(C) and unit twist (D) profiles. Bend and twist angles assigned at position
i correspond to the value computed for (i-3, i) and (i, i+3) and for (i-3, i),
respectively.
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